Company: INMB
Filing Date: 2025-05-09
Form Type: DEFR14A
Source: 0001213900-25-041516
Chunk: 4

Company: Inmune Bio, Inc.
Filing Date: 2025-05-09
Form: DEFR14A
Chunk 4
---
 submitting the selection of CBIZ CPAs to our stockholders for ratification at the Meeting as a matter of good corporate practice and
because we value our stockholders’ views on our independent registered public accounting firm.

If the appointment of CBIZ CPAs is not ratified,
the audit committee will evaluate the basis for the stockholders’ vote when determining whether to continue the firm’s engagement,
but may ultimately determine to continue the engagement of the firm or another audit firm without re-submitting the matter to stockholders.
Even if the appointment of CBIZ CPAs is ratified, the audit committee may terminate the engagement of the firm and direct the appointment
of another independent auditor at any time during the year if it determines that such an appointment would be in the best interests of
our Company and our stockholders.

Representatives of CBIZ CPAs are not expected
to attend the Meeting.

Change in Independent Registered Public Accounting Firm

On November 1, 2024, CBIZ CPAs acquired the attest
business of Marcum LLP. On May 7, 2025, with the approval of the audit committee, the Company dismissed Marcum LLP as our independent
registered public accounting firm. Previously, Marcum LLP served as our independent registered public accounting firm from August 5, 2018
to May 7, 2025, and reported on our financial statements for the years ended December 31, 2018, 2019, 2020, 2021, 2022, 2023 and 2024.

The audit report of Marcum LLP on the Company’s
consolidated financial statements as of and for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or
a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope, or accounting principles, except that the report
included an explanatory paragraph relating to substantial doubt about the Company’s ability to continue as a going concern.

During the fiscal years ended December 31, 2024
and 2023 and through May 7, 2025, there were no (1) “disagreements” (as defined in Item 304(a)(1)(iv) of Regulation S-K and
the related instructions) between the Company and Marcum LLP on any matter of accounting principles or practices, financial statement
disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Marcum LLP, would have caused Marcum